和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00013 和黄医药

休市中 08-28 16:08:33

19.830

+0.000

0.00%

最高20.040	最低19.580	成交量421.20万
今开19.840	昨收19.830	日振幅2.32%
总市值172.92亿	流通市值172.92亿	总股本8.72亿
成交额8,364万	换手率0.48%	流通股本8.72亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00013","market":"HK","secType":"STK","nameCN":"和黄医药","latestPrice":19.83,"timestamp":1787904513002,"preClose":19.83,"halted":0,"volume":4212000,"delay":0,"changeRate":0,"floatShares":872000000,"shares":872000000,"eps":4.078167644383097,"marketStatus":"休市中","change":0,"latestTime":"08-28 16:08:33","open":19.84,"high":20.04,"low":19.58,"amount":83639932,"amplitude":0.023197,"askPrice":19.83,"askSize":39000,"bidPrice":19.79,"bidSize":33500,"shortable":3,"etf":0,"ttmEps":0.15834300592903972,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788139800000},"marketStatusCode":7,"adr":0,"listingDate":1624982400000,"exchange":"SEHK","adjPreClose":19.83,"openAndCloseTimeList":[[1787880600000,1787889600000],[1787893200000,1787904000000]],"volumeRatio":0.9358131700725225,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00013","defaultTab":"news","newsList":[{"id":"2662882037","title":"港股公告掘金 | 蜜雪集团上半年实现收入约152.16亿元 同比增长2.3% 全球门店网络持续扩容","url":"https://stock-news.laohu8.com/highlight/detail?id=2662882037","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662882037?lang=zh_cn&edition=full","pubTime":"2026-08-28 09:05","pubTimestamp":1787879123,"startTime":"0","endTime":"0","summary":"重大事项：和黄医药(00013)：爱领达(凡瑞格拉替尼)获中国国家药监局批准用于治疗FGFR2融合/重排的肝内胆管癌患者映恩生物-B(09606)与Genentech订立全球研发合作及许可协议 以基于公司DUPAC新型有效载荷平台开发下一代ADC石四药集团(02005)已取得国家药监局有关钆布醇注射液(7.5ml：4.5354g)的药品生产注册批件固生堂(02273)：收购YC TCM (TAMA","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1487692.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","HK0000252152.HKD","BK1616","HK0000500386.USD","02097","00013","BK1587","09606","02273","LU2460026573.USD","HK0000252160.HKD","BK1161","BK1219","BK1191","BK1588","02005","BK4585","BK4588","LU2543165471.USD","BK1233","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197995901","title":"和黄医药(00013)口服FGFR抑制剂爱领达获NMPA附条件批准治疗FGFR2融合/重排晚期肝内胆管癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1197995901","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197995901?lang=zh_cn&edition=full","pubTime":"2026-08-28 08:06","pubTimestamp":1787875577,"startTime":"0","endTime":"0","summary":"2026年8月28日，和黄医药（中国）有限公司公告，其自主研发的高选择性FGFR1/2/3抑制剂凡瑞格拉替尼已获国家药品监督管理局附条件批准，用于治疗既往接受过系统性治疗、伴有成纤维细胞生长因子受体2融合或重排的晚期、转移性或不可手术切除的肝内胆管癌成人患者。和黄医药代理首席执行官兼首席财务官郑泽锋表示，爱领达的批准填补了中国伴FGFR2改变的晚期肝内胆管癌靶向治疗空白，公司已准备加速推进该药品的商业化。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662034052","title":"和黄医药：爱领达获国家药监局批准用于治疗FGFR2融合/重排肝内胆管癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2662034052","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662034052?lang=zh_cn&edition=full","pubTime":"2026-08-28 08:03","pubTimestamp":1787875380,"startTime":"0","endTime":"0","summary":"南财智讯8月28日电，和黄医药（00013.HK）发布自愿公告，公司自主研发的创新药凡瑞格拉替尼（商品名：爱领达?，英文商标：ATLED?）新药上市申请获中国国家药品监督管理局附条件批准，用于治疗既往接受过系统性治疗、且具有成纤维细胞生长因子受体（FGFR）2融合或重排的晚期、转移性或不可手术切除的肝内胆管癌成人患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608283857328767.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608283857328767.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["00013","BK1191","BK1587","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134646933","title":"和黄医药宣布爱优特®（凡瑞替尼）获国家药监局批准，用于治疗FGFR2融合/重排的肝内胆管癌患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1134646933","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134646933?lang=zh_cn&edition=full","pubTime":"2026-08-28 08:01","pubTimestamp":1787875273,"startTime":"0","endTime":"0","summary":"和黄医药正式宣布，其自主研发的创新药物爱优特已获得中国国家药品监督管理局的批准。该药物适用于携带FGFR2基因融合或重排的肝内胆管癌患者的治疗。肝内胆管癌是一种侵袭性强、预后较差的恶性肿瘤，而FGFR2融合/重排是其中一类重要的分子亚型。爱优特作为一种高选择性FGFR抑制剂，其上市将有望填补该细分领域的临床需求缺口。这一批准决定，基于对药物疗效与安全性的综合评估，反映了监管机构对创新疗法价值的认可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1588","BK1587","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660641958","title":"研报掘金丨中金：和黄医药赛沃替尼海外申报现曙光，目标价升至26港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660641958","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660641958?lang=zh_cn&edition=full","pubTime":"2026-08-19 10:47","pubTimestamp":1787107663,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4588","BK1191","00013","BK4007","BK1587","BK4531","BK1588","EWH","BK4585","HCM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120165229","title":"和黄医药（中国）有限公司：破产程序仍在进行中，截至本公告日期，公司尚不明确程序结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1120165229","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120165229?lang=zh_cn&edition=full","pubTime":"2026-08-18 17:14","pubTimestamp":1787044447,"startTime":"0","endTime":"0","summary":"和黄医药（中国）有限公司对外披露，目前公司正处于破产程序进行阶段。然而，需要明确指出的是，截至这份公告发布的具体日期，该司法程序的最终走向与结果，对于公司而言，依旧是一个未知数。换句话说，事态的后续发展尚未明朗化，公司方面也无法给出确切的预判或结论。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK1191","BK1588","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132417451","title":"和黄医药（00013）披露前董事任职公司在以色列进入无力偿债程序","url":"https://stock-news.laohu8.com/highlight/detail?id=1132417451","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132417451?lang=zh_cn&edition=full","pubTime":"2026-08-18 17:06","pubTimestamp":1787044012,"startTime":"0","endTime":"0","summary":"2026年8月18日，和黄医药公告称，应香港联交所上市规则第13.51B条及第13.51条要求，公司披露主席兼非执行董事艾乐德博士相关信息变动：其曾任董事的S.D. Sight Diagnostics Ltd.已在以色列启动无力偿债程序。目前，该程序仍在进行中，尚无最终结果。和黄医药董事会表示，上述无力偿债程序不涉及本集团或其业务，因此不会对集团的业务及运营造成影响。除上述披露外，公司暂无其他须向股东特别通报的事项。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660556894","title":"中金：维持和黄医药(00013)跑赢行业评级 上调目标价至26港币","url":"https://stock-news.laohu8.com/highlight/detail?id=2660556894","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660556894?lang=zh_cn&edition=full","pubTime":"2026-08-18 09:12","pubTimestamp":1787015578,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，基本维持和黄医药2026年/2027年归母净利润预测5,555万美元/8,865万美元不变。该行维持跑赢行业评级，考虑到SAFFRON成功，赛沃替尼海外成功率上调，根据DCF模型，上调目标价9.24%至26港币，较当前股价有29.48%的上行空间。该行认为本次公告PFS和OS均取得阳性结果，有力支撑赛沃替尼在美国等海外核心市场的申报。根据海外合作伙伴阿斯利康中报，其预计有望2H26递交上市申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1481153.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00013","HCM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660810460","title":"和黄医药宣布沃瑞沙®和泰瑞沙®的联合疗法在SAFFRON全球III期研究中显示出具有统计学和临床意义的PFS和OS改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2660810460","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660810460?lang=zh_cn&edition=full","pubTime":"2026-08-17 11:12","pubTimestamp":1786936320,"startTime":"0","endTime":"0","summary":"继SACHI III期研究支持了该疗法在中国获批后，SAFFRON全球研究的结果进一步印证了其坚实的疗效，并将为泰瑞沙和沃瑞沙联合疗法的全球注册提供明确的数据支持。\" 沃瑞沙和泰瑞沙联合疗法的安全性特征与已知的各药物的安全性保持一致，且没有发现新的安全性问题。基于SACHI III期研究，沃瑞沙和泰瑞沙联合疗法已于中国获批用于治疗接受EGFR TKI治疗后疾病进展的伴有MET扩增的EGFR突变的局部晚期或转移性非小细胞肺癌患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5027243_ZH27243_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5027243_ZH27243_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4588","III","BK4211","BK1588","PFS","BK4195","BK4585","BK1191","00013","BK4007","BK1587","HCM","BK4531","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660210915","title":"和黄医药盘中涨近9% 沃瑞沙联合泰瑞沙联合疗法取得积极的顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2660210915","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660210915?lang=zh_cn&edition=full","pubTime":"2026-08-17 10:24","pubTimestamp":1786933440,"startTime":"0","endTime":"0","summary":"沃瑞沙和泰瑞沙联合疗法的安全性特征与已知的各药物的安全性保持一致 ，且没有发现新的安全性问题。基于SACHI III期研究，沃瑞沙和泰瑞沙联合疗法已于中国获批用于治疗接受EGFR TKI治疗后疾病进展的伴有MET扩增的EGFR突变的局部晚期或转移性非小细胞肺癌患者。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-17/doc-ininqtnx7878919.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HCM","BK4588","BK1587","BK1191","BK4531","BK4585","00013","BK4007","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173380078","title":"港股创新药概念股盘中走强，和黄医药涨超7%，药明生物、金斯瑞生物科技涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1173380078","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173380078?lang=zh_cn&edition=full","pubTime":"2026-08-17 10:08","pubTimestamp":1786932515,"startTime":"0","endTime":"0","summary":"8月17日，港股创新药概念股盘中走强，$和黄医药(00013)$涨超7%，$药明生物(02269)$、$海西新药(02637)$、$金斯瑞生物科技(01548)$涨超5%，$药明康德(02359)$、$药明合联(02268)$涨超4%，$信达生物(01801)$、$石药集团(01093)$涨超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000306701.USD","LU0320764599.SGD","BK1610","LU1880383366.USD","IE00B031HY20.USD","LU1046422090.SGD","LU0359202008.SGD","LU1226287875.USD","BK4588","LU0348735423.USD","BK1589","02637","HK0000320264.USD","KURE","LU1807302812.USD","LU0348766576.USD","LU0315179316.USD","01801","LU0856984785.SGD","LU0979878070.USD","MEDX","LU0417516738.SGD","LU0516423091.SGD","LU1152091754.HKD","LU2097828474.EUR","BK1574","LU0516422440.USD","LU0067412154.USD","BK1587","HK0000306685.HKD","LU0469268626.HKD","SG9999004220.SGD","LU2097828805.USD","LU0029874061.USD","BK1583","LU0880133367.SGD","LU1152091168.USD","LU0417516902.SGD","LU1242518857.USD","LU0314109678.HKD","LU1969619763.USD","LU0588546209.SGD","159992","HK0000320223.HKD","LU2039709279.SGD","LU1951186391.HKD","SG9999002463.SGD","LU2045819591.USD","LU0819121731.USD","LU1226288170.HKD","LU0348825331.USD","LU1813983027.USD","LU2488822045.USD","LU0823426308.USD","LU0823426480.USD","LU1008478684.HKD","LU0708995583.HKD","LU0072913022.USD","LU0501845795.SGD","IE0008369823.USD","LU2097828557.USD","02268","LU1226287529.USD","LU1188198961.HKD","IE00BZ08YS42.EUR","SG9999002562.SGD","LU0456827905.SGD","VXUS","LU0463099449.HKD","LU0456846285.SGD","IE00B5MMRT66.SGD","BK1161","LU0128526141.USD","LU2125910500.SGD","LU1328277881.USD","BK4007","LU1226288253.USD","LU2097828714.EUR","BK4531","LU0455707207.USD","LU0326950275.SGD","LU0039217434.USD","LU0307460666.USD","06978","IE00B543WZ88.USD","LU0516423174.USD","IE0008368742.USD","LU0516422952.EUR","01093","LU0327786744.USD","LU2328871848.SGD","LU1993786604.SGD","LU3063872942.SGD","IE00B0JY6N72.USD","BK1521","LNGR","BK1141","01548","LU0051755006.USD","SG9999014674.SGD","LU1794554557.SGD","02359","BK1515","IE00BZ08YT58.USD","00013","LU0244354667.USD","LU1242518931.SGD","BK1588","HCM","BK1576","KCAI","LU0140636845.USD","LU1226287792.SGD","HK0000165453.HKD","LU1960683339.HKD","LU2097828631.EUR","IBBQ","LU0052750758.USD","02269","LU1720050803.USD","LU0502904849.HKD","LU0516422366.SGD","LU0572944931.SGD","BK4585","LU0359201612.USD","BK1191","IE00BZ08YR35.GBP","LU1688375341.USD","LU0181495838.USD","LU2242644610.SGD","LU0348767384.USD","LU0043850808.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660109821","title":"港股异动 | 和黄医药(00013.HK)早盘涨近9% 沃瑞沙联合泰瑞沙联合疗法取得积极的顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2660109821","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660109821?lang=zh_cn&edition=full","pubTime":"2026-08-17 09:44","pubTimestamp":1786931058,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1587","BK1191","00013","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132185322","title":"和黄医药：奥帕替尼联合泰瑞沙改善EGFR突变非小细胞肺癌III期试验生存数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1132185322","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132185322?lang=zh_cn&edition=full","pubTime":"2026-08-17 08:02","pubTimestamp":1786924928,"startTime":"0","endTime":"0","summary":"和黄医药（中国）宣布，其药物奥帕替尼（Orpathys）与泰瑞沙（Tagrisso）的联合疗法，在针对EGFR突变型非小细胞肺癌（NSCLC）的III期临床试验中，显著提升了患者的生存率。这一积极结果，为肺癌治疗领域注入了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00013","BK1588","BK1587","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124468335","title":"和黄医药宣布：Orpathys®联合Tagrisso®在MET驱动的EGFR突变肺癌中展现显著生存获益","url":"https://stock-news.laohu8.com/highlight/detail?id=1124468335","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124468335?lang=zh_cn&edition=full","pubTime":"2026-08-17 08:01","pubTimestamp":1786924870,"startTime":"0","endTime":"0","summary":"和黄医药今日发布重磅消息：其研发的Orpathys联合阿斯利康的Tagrisso，在针对MET驱动的EGFR突变非小细胞肺癌患者中，展现出具有统计学意义和临床价值的无进展生存期与总生存期双重改善。这一突破性进展，尤其适用于那些在Tagrisso单药治疗后出现疾病进展的患者。MET基因扩增或过表达，正是导致EGFR突变肺癌对Tagrisso产生耐药性的关键机制之一。而Orpathys作为一种高选择性MET抑制剂，能够精准靶向这一通路，从而恢复肿瘤对治疗的敏感性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1588","BK1191","BK1587","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657155005","title":"【券商聚焦】申万宏源维持和黄医药（00013）买入评级 指呋喹替尼海外持续放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2657155005","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657155005?lang=zh_cn&edition=full","pubTime":"2026-08-05 14:38","pubTimestamp":1785911894,"startTime":"0","endTime":"0","summary":"金吾财讯 | 申万宏源发布研报指，和黄医药 2026年上半年收入2.78亿美元，同比增长0.2%，净利润为1,600万美元，同比下降96.5%，主因去年同期确认上海和黄药业处置收益，业绩符合预期。呋喹替尼海外市场持续拓展是核心亮点。研报预计，随着市场份额及医保覆盖范围扩大，其海外销售额有望进一步增长。考虑到呋喹替尼海外市场持续放量，申万宏源将26年的每股盈利预测从0.04美元上调至0.06美元，将27年预测从0.08美元上调至0.09美元，新增28年预测为0.10美元。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987535","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCM","000166","KCE","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176871663","title":"和黄医药更新2026年7月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1176871663","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176871663?lang=zh_cn&edition=full","pubTime":"2026-08-03 16:40","pubTimestamp":1785746415,"startTime":"0","endTime":"0","summary":"和黄医药（中国）有限公司于2026年8月3日发布了截至2026年7月31日的证券变动月报。报告显示，公司在本报告期内已发行及注册股本维持稳定，公示的股本数量和所持库藏股份均未出现变动。截至2026年7月31日，公司已发行普通股数量为872,335,120股，库藏股份数量为0股，较上月末均无变化。公司进一步确认，当前公众持股量满足香港联合交易所有限公司主板上市规则的相关要求。本次公告由公司非执行董事兼公司秘书施熙德签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656342224","title":"瑞银：降和黄医药(00013)目标价至29.5港元 续予“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2656342224","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656342224?lang=zh_cn&edition=full","pubTime":"2026-08-03 11:24","pubTimestamp":1785727484,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞银发布研报称，和黄医药(00013)上半收入同比增0.2%，大致符合该行预期。肿瘤或免疫业务收入同比增长13%，高于该行预期；纯利1,590万美元，去年同期为4.55亿美元，主要是由于去年同期确认了出售上海医药合营的一次性收益。该行将阿斯利康的里程碑延后至2027年，并修正开支预测，导致2026年的每股盈测下调，而2027年的预测则已由6美仙上调至8美仙。该行将公司目标价由29.7港元下调至29.5港元，续予“买入”评级。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475127.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HCM","EWH","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656818342","title":"大行评级丨瑞银：微降和黄医药目标价至29.5港元，续予“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2656818342","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656818342?lang=zh_cn&edition=full","pubTime":"2026-08-03 10:57","pubTimestamp":1785725823,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4585","BK4007","BK1191","00013","BK1588","HCM","BK4531","EWH","BK4588","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655362398","title":"和黄医药发布中期业绩 2026年上半年净利骤降96.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655362398","media":"经济参考网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655362398?lang=zh_cn&edition=full","pubTime":"2026-07-31 22:06","pubTimestamp":1785506816,"startTime":"0","endTime":"0","summary":"和黄医药（中国）有限公司（简称“和黄医药”，00013.HK）7月30日晚间发布2026年中期业绩公告，上半年公司实现收入总额2.78亿美元，同比增长0.22%；归属于母公司所有者的净利润为1592.80万美元，同比下降96.50%，主要由于2025年同期包含出售上海和黄药业45%股权所得一次性收益4.16亿美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607313828677510.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607313828677510.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","BK4585","BK4588","BK4007","BK1588","00013","BK4531","BK1587","HCM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655938258","title":"粤十数智、星宇股份、汉得信息递表港交所；和黄医药、先声药业、美图公司发布2026年中期业绩预告丨港交所早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2655938258","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655938258?lang=zh_cn&edition=full","pubTime":"2026-07-31 07:01","pubTimestamp":1785452474,"startTime":"0","endTime":"0","summary":"｜2026年7月31日星期五｜NO.1粤十数智、星宇股份、汉得信息递表港交所据港交所7月29日披露，深圳粤十数智股份有限公司（以下简称粤十数智）、常州星宇车灯股份有限公司（以下简称星宇股份，SH601799）、上海汉得信息技术股份有限公司（以下简称汉得信息，SZ300170）已向港交所主板递交上市申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607313827197718.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607313827197718.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0070","BK1612","IE00B5MMRT66.SGD","IPOS","LU0620787316.HKD","BK0188","BK1095","02096","LU0164939612.USD","01357","LU2125910500.SGD","LU0082770016.SGD","SG9999006597.SGD","LU2125910849.SGD","BK4531","SG9999001093.SGD","BK0264","LU0082770016.USD","LU2045819591.USD","BK1587","BK0065","HCM","00013","601799","BK1618","BK1583","BK1191","300170","IE00BPRC5H50.USD","BK1588","BK4588","BK4585","BK4007","BK0231","IE00B543WZ88.USD","BK1613","BK1609"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hutch-med.com","stockEarnings":[{"period":"1week","weight":0.003},{"period":"1month","weight":0.1041},{"period":"3month","weight":0.0824},{"period":"6month","weight":-0.1264},{"period":"1year","weight":-0.1518},{"period":"ytd","weight":-0.0383}],"compareEarnings":[{"period":"1week","weight":-0.0163},{"period":"1month","weight":-0.0086},{"period":"3month","weight":0.016},{"period":"6month","weight":-0.0393},{"period":"1year","weight":0.0234},{"period":"ytd","weight":-0.0018}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和黄医药（中国）有限公司是一间主要从事制造及销售药物的投资控股公司。该公司主要通过两个分部运营业务。肿瘤免疫业务分部从事发现、开发和商业化用于治疗癌症和免疫性疾病的靶向疗法和免疫疗法。其中研发包括涵盖药物发现、开发、生产及监管职能的研发活动，上市产品包括通过研发活动开发的药物的已开具发票的销售、推广、生产及分销。其他业务分部从事其他商业化业务，包括其他处方药物及保健品的销售、推广、生产及分销。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.066388},{"month":2,"riseRate":0.6,"avgChangeRate":0.075835},{"month":3,"riseRate":0.2,"avgChangeRate":-0.093928},{"month":4,"riseRate":0.4,"avgChangeRate":0.010831},{"month":5,"riseRate":0,"avgChangeRate":-0.149846},{"month":6,"riseRate":0.4,"avgChangeRate":0.004362},{"month":7,"riseRate":1,"avgChangeRate":0.132805},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.043633},{"month":9,"riseRate":0.6,"avgChangeRate":-0.004654},{"month":10,"riseRate":0.2,"avgChangeRate":-0.040611},{"month":11,"riseRate":0.4,"avgChangeRate":0.13917},{"month":12,"riseRate":0.4,"avgChangeRate":-0.030017}],"exchange":"SEHK","name":"和黄医药","nameEN":"HUTCHMED"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和黄医药(00013)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和黄医药,00013,和黄医药股票,和黄医药股票老虎,和黄医药股票老虎国际,和黄医药行情,和黄医药股票行情,和黄医药股价,和黄医药股市,和黄医药股票价格,和黄医药股票交易,和黄医药股票购买,和黄医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和黄医药(00013)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}